[ad_1]
The drug discovery and development company EVOTEC and the French pharmaceutical company Sanofi have successfully implemented their plans to set up a platform for accelerated research and development of anti-infectives. . Under this agreement, Hamburg-based TecDAX will integrate the Sanofi anti-infective unit and the associated anti-infective research portfolio into its own organization.
EVOTEC plans to advance the development of the infectious disease pipeline and launch new research initiatives on open innovation in the field of anti-infectives. The focus will be first on antibiotic resistance, infections caused by superbugs, tuberculosis, malaria and the development of new antiviral therapies with new mechanisms of action.
The agreement will result in guaranteed payments from Sanofi over the next five years, including an upfront payment of 60 million euros.
HAMBURG (Dow Jones)
[ad_2]
Source link
